Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
46-60 of 231
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiersGFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiersCK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiersAdvancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Adil Harroud, MD
Dylan Hamitouche
Ryan Quigley
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiersUnderstanding Accelerated Biological Aging in Pediatric MS
Jennifer Yang, MD
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiersMultiple Sclerosis Without Borders: Taking a Global View
Andrew Wilner, MD, FACP, FAAN
Victor Rivera, MD
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiersMultiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Raphael Schneider, MD, PhD, FRCPC, CIP
- advertisement
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology AcademyBeyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Ashkan Shoamanesh, MD
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology AcademyOCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Mike Sharma, MD, MSc, FRCPC
Optimizing Vitamin D Supplementation in MS Care
NeuroFrontiersOptimizing Vitamin D Supplementation in MS Care
Evaluating Structured Interventions for Cognitive Support in MS
AudioAbstractsEvaluating Structured Interventions for Cognitive Support in MS
Hallie Blevins, PhD
The Role of Neurofilament Light Chain in MS Management
NeuroFrontiersThe Role of Neurofilament Light Chain in MS Management
Parkinson’s Research in Focus: Translating Science Into Clinical Progress
NeuroFrontiersParkinson’s Research in Focus: Translating Science Into Clinical Progress
Jerome Lisk, MD, MBA, M.S., FAAN
Michael Salvatore, PhD
Vicki Nejtek-Salvatore, PhD
- advertisement
Cracking the Migraine Code: How AI May Transform Diagnosis and Treatment
On the Frontlines of MigraineCracking the Migraine Code: How AI May Transform Diagnosis and Treatment
Ashley Baker, MSN, PMHNP
Chia-Chun Chiang, MD
Challenges and Opportunities in Migraine Management
On the Frontlines of MigraineChallenges and Opportunities in Migraine Management
Charles Turck, PharmD, BCPS, BCCCP
Yulia Orlova, MD
How Daily Light Habits Influence Migraine in Adolescents
On the Frontlines of MigraineHow Daily Light Habits Influence Migraine in Adolescents
Charles Turck, PharmD, BCPS, BCCCP
Carlyn Patterson Gentile, MD
